The study undertaken by Astute Analytica foresees a tremendous growth in revenue of the market for global opioid withdrawal syndrome (OWS) market from US$ 1,068.3 Million in 2021 to US$ 2,633.4 Million by 2030. The market is anticipated to grow at a CAGR of 10.4% during the forecast period 2022-2030.
Get a Free Sample Copy of this Report@ https://www.astuteanalytica.com/request-sample/opioid-withdrawal-syndrome-market
The withdrawal symptoms are generally not life-threatening, but it causes tremendous psychological and physical disturbance that often-led people to start reuse of opioids to avoid withdrawal symptoms. This leads to a continuous cycle of stopping and resuming drug use, which makes it difficult to quit later on. When the use of opiate drugs is stopped, it may produce several withdrawal symptoms and collectively these symptoms are called Opiate Withdrawal Syndrome (OWS). Opiate withdrawal symptoms may range from mild to severe, depending on how dependent the individual is on an opioid drug. Also, the prevalence of OWS is estimated to be same in both males and females. Only one non-opioid drug, Lucemyra has received an FDA approval till date.
On the basis of therapy, buprenorphine is estimated to have the highest market share in 2021 as it has long half-life, high potency and ceiling effect’ for both euphoric sensation and adverse effects make it an optimal treatment alternative for patients presenting to the ED with opioid withdrawal. Moreover, the lucemyra (lofexidine) segment is expected to project the highest CAGR during the forecast period. Furthermore, based on country, the US is the dominating region in the opioid withdrawal syndrome (OWS) market in 2021 and is also expected to project the highest CAGR during the forecast period owing to increasing prevalence of chronic diseases, which is leading to the rise in the adoption of opioids for pain management.
Market Dynamics and Trends
The increasing cases of opioid addiction and increasing engagement by private and public institutions will boost the global opioid withdrawal syndrome (OWS) market during the forecast period. The general population suffers from a wide range of severe and chronic diseases including cardiovascular, pain arising from injuries and other conditions. These diseases often cause chronic pain amongst the patients that are managed with the consumption of painkillers mostly opioids. While the pain reduces, there is a greater chance that the patient may get addicted to these drugs. Moreover, the growing dependency on these drugs and abrupt discontinuation may lead to patient suffering from withdrawal symptoms. Hence the patients continue to use these opioids that sharply increases the probability of fatal consequences for the patients. Furthermore, increasing involvement of private and government institute in opioid withdrawal syndrome therapy is the key factor for the growth of the market. The number of individuals suffering from opioids addiction has substantially increased and it led several governments to get involved on a wide scale to tackle this crisis. For example, in the US, Department of Health and Human Services (HHS) in 2017 declared opioid crisis as public health emergency to combat the problem of OWS, hence these initiatives drive the growth of opioid withdrawal syndrome market over the forecast period.
Adverse side effects of opioids is a restraining factor which inhibits the growth of the global opioid withdrawal syndrome market during the forecast period. These effects are due to addiction of opioid even as a treatment. Some of the adverse reactions of these drugs include vomiting, bladder pain, cramps, diarrhea, respiratory issues, bone/joint pains and muscle aches among others. Furthermore, in certain severe cases of adverse reactions, the patients may also suffer from psychological problems such as depression. Hence, due to increase in adverse effects of opioids, end consumers are shifting to non-opioid drugs that may hamper the growth of opioid based opioid withdrawal syndrome market.
Global Opioid Withdrawal Syndrome (OWS) Market Country Wise Insights
- US Opioid Withdrawal Syndrome (OWS) Market-
US holds the major share in terms of revenue in the global opioid withdrawal syndrome (OWS) market in 2021 and is also projected to grow with the highest CAGR during forecast period due to the presence of leading market players and the approval of OWS therapies in the country. Also, US World Meds is evaluating its FDA approved therapy, Lofexidine for its safety and efficacy in the opioid tapering procedure for opioid withdrawal. Moreover, based on therapy, buprenorphine is estimated to have the highest market share in 2021.
- UK Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and treatable OWS cases are continuously decreasing in the United Kingdom. Britannia Pharmaceuticals has been offering OWS therapy, Britlofex for over two decades. This has led to the increase in the awareness of opioid use disorders and the decline in the prevalence of OWS cases in the country. Therefore, a slight increase has been estimated in the OWS market in United Kingdom over the forecast period due to the high incidence rate of chronic diseases, such as cancer and cardiac diseases, leads to the increase in the adoption of opioids for pain management. Moreover, in terms of therapy, the lucemyra (lofexidine) segment is expected to project the highest CAGR during the forecast period.
- Germany Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and treatable OWS cases are continuously increasing in the Germany. Opioid therapy in the treatment of chronic pain conditions in Germany is highly considered. Germany contributes modest share in the OWS market in EU5 nations. Furthermore, based on therapy, buprenorphine is estimated to have the highest market share in 2021.
- France Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and treatable OWS cases are continuously increasing in France. Though, post 2017, the prevalence rate of OWS cases in France has decreased, compared to 2015, 2016 and 2017 due to the fact increasing awareness of OUD and OWS in the country, driven by the established healthcare infrastructure and the expansion of market players in France.
- Spain Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and treatable OWS cases are continuously increasing in Spain. Though, the prevalence rate of OWS cases in Spain is low, compared to Germany, the United States and other economies. This is due to the rising awareness related to OUD by the awareness campaigns organized by the governmental bodies. Also, considering the high presence of OUD patients, the market players are considering expansion in Spain.
- Italy Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and treatable OWS cases are continuously decreasing in Italy. Post 2017, the prevalence of OWS cases is decreasing at a modest rate in the country, leading to the decline in the demand for OWS in Italy. Moreover, the laws impacted the consumption of opioids in the country, which in turn, has decreased the cases of OUD and OWS in the country.
- Japan Opioid Withdrawal Syndrome (OWS) Market-
The diagnosis and therapeutics rate of OWS is continuously decreasing in Japan. The prevalence rate of OWS cases increased in Japan till 2018. The prevalence rate declined slightly in 2019 in Japan. The adoption rate of OWS in Japan is low, due to low prescriptions by the doctors for opioids in the country. Moreover, in Japan, opioids for acute pain are not typically covered by insurance. Furthermore, based on therapy, the buprenorphine dominated the opioid withdrawal syndrome (OWS) market in 2021.
Global Opioid Withdrawal Syndrome (OWS) Market is highly competitive in order to increase their presence in the marketplace. Some of the key players operating in the global opioid withdrawal syndrome (OWS) market include US Worldmeds LLC, Aphios Corporation, Chiesi Farmaceutici S.p.A., Titan Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., Alkermes and Indivior PLC among others.
Global Opioid Withdrawal Syndrome (OWS) Market is segmented based on therapy and country. The industry trends in the global opioid withdrawal syndrome (OWS) market are sub-divided into different categories in order to get a holistic view of the global marketplace.
Following are the different segments of the Global Opioid Withdrawal Syndrome (OWS) Market:
By Therapy segment of the Global Opioid Withdrawal Syndrome (OWS) Market is sub-segmented into:
- Lucemyra (Lofexidine)
- Others (Britlofex, Masimo Bridge, etc.)
By Country segment of the Global Opioid Withdrawal Syndrome (OWS) Market is sub-segmented into:
Access Full Report@ https://www.astuteanalytica.com/request-sample/opioid-withdrawal-syndrome-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Follow US: LinkedIn | Twitter